There is mixed evidence about the role of PIGR in cancer, but some evidence suggests that PIGR promotes oncogenic AKT activity with downstream effects on GSK3B/β-catenin that are reversed by AKT inhibition (23). This evidence concerns the gene GSK3B and cancer.